Research & Publications

Translational research has always been the linchpin of Lifedoc’s clinical framework, further enabling us to provide healthcare that is quality-oriented and data-driven. Over the last 15 years, research has remained an integral part of our efforts to maximize the applicability of health data. With active participation in industry-sponsored and investigator-initiated research, we aim to to inform emerging treatments and continually refine our clinical model for the ultimate benefit of the patient. This focus allows us to continually develop data to support our evidence-based approach, ensuring that our patients receive the most effective healthcare and clinical interventions. Ultimately, this allows us to fulfill our mission of establishing Lifedoc as a reference model for researchers and practitioners studying the development and prevention of cardiometabolic conditions.

Take a look at our past and ongoing trials, research partnerships as well as some of our published/presented studies below.

Interested in working with our research site? Contact us.

Quality care for all. A kid playing doctor.

Research Partnerships

Novo Nordisk

Industry-sponsored Clinical Trials

Ongoing Trials

– Boehringer-Ingleheim – Safety and Efficacy of SGLT-2 and DPP-4 in Type 2 Diabetes, Children 10 – 17 years of age.

Past Trials

– Janssen – Safety and Efficacy of SGLT-2  in Type 2 Diabetes, Adults – Recognized as Highest Recruiting/Retaining Site in the US

– Novo Nordisk – Safety and Efficacy of Liraglutide in Overweight and Obesity, Children and Adolescents 10-17 years of age – Recruited First and Second Patient Globally

–  Novo Nordisk – Safety and Efficacy of Liraglutide and Metformin in Type 2 Diabetes, Children and Adolescents 10-17 years of age – Recognized as Highest Recruiting Site in the US

Notable Publications

Transcultural diabetes nutrition algorithm (tDNA): Venezuelan application

Published: Nutrients
Date:
Authors: Ramfis Nieto-Martínez 1 , Osama Hamdy 2 , Daniel Marante 3 , María Inés Marulanda 4 , Albert Marchetti 5 , Refaat A Hegazi 6 , Jeffrey I Mechanick 7
Abstract:
Medical nutrition therapy (MNT) is a necessary component of comprehensive type 2 diabetes (T2D) management, but optimal outcomes require culturally-sensitive implementation.

A pilot study of QT interval analysis in overweight and obese youth

Published: Applied Nursing Research
Date:
Authors: Shirleatha Lee 1 , Patricia Ann Cowan, Pedro Velasquez-Mieyer
Abstract:
This descriptive pilot study examined if manual corrected QT (QTc) interval measures obtained from a standard 12-lead electrocardiogram (ECG) correlated with automated 24-hour ambulatory Holter QTc measures in 30 overweight and obese youth aged 12-17 years.

Prediabetes and blood pressure effects on heart rate variability, QT-interval duration, and left ventricular hypertrophy in overweight-obese adolescents

Published: The Journal of Pediatric Nursing
Date:
Authors: Shirleatha Lee 1 , Patricia Ann Cowan, Glenn T Wetzel, Pedro Velasquez-Mieyer
Abstract:
This ancillary, descriptive correlational study examined the effect of glucose regulation, blood pressure (BP), and their combined effects on cardiac autonomic function in 128 overweight-obese 11-18-year-olds.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Published: The Lancet
Date:
Authors: Richard M Bergenstal 1, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter, DURATION-2 Study Group
Abstract:
Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin.
1 … 6 7 8 9 10 … 12

Contact Us